文献速递消化道肿瘤与早癌消化内镜

结直肠癌免疫检查点阻断应答的免疫基因组学:KEYNOTE 177试验及验证队列分析

Immunogenomics of Colorectal Cancer Response to Checkpoint Blockade: Analysis of the KEYNOTE 177 Trial and Validation Cohorts.
PubMed 文献 · Gastroenterology · 2021-06-29

该研究对29例接受帕博利珠单抗(KEYNOTE 177)或纳武利尤单抗治疗的结直肠癌患者进行多区域全外显子与RNA测序,结合T细胞受体测序、成像质谱流式及空间分析。发现高突变结直肠癌对抗PD1治疗应答与肿瘤突变负荷无关,而与免疫原性突变高克隆性、克隆扩增T细胞、Wnt信号低活化、干扰素γ通路失调及活跃免疫逃逸相关;应答者富含与PDL1+抗原提呈巨噬细胞相互作用的细胞毒性PD1+CD8 T细胞。

要点

  • 高突变结直肠癌抗PD1应答不依赖肿瘤突变负荷,而与免疫原性突变克隆性相关。
  • 应答者肿瘤微环境中细胞毒性PD1+CD8 T细胞与PDL1+抗原提呈巨噬细胞相互作用丰富。
  • 抗PD1药物可能通过释放CD8 T细胞与巨噬细胞间的PD1-PDL1相互作用发挥抗肿瘤活性。

核心结论

  • 肿瘤突变负荷作为结直肠癌抗PD1免疫治疗应答预测因子存在局限,应答更取决于免疫原性突变克隆性及特定肿瘤微环境细胞互作。

研究设计与样本

  • 研究纳入29例接受帕博利珠单抗或纳武利尤单抗治疗的结直肠癌患者,每例肿瘤选取多个T细胞浸润区域,共738个区域,分为发现队列和验证队列。

主要发现

  • 在高突变结直肠癌中,抗PD1免疫治疗应答与肿瘤突变负荷无关,而与免疫原性突变高克隆性、克隆扩增T细胞、Wnt信号低活化、干扰素γ通路失调及活跃免疫逃逸机制相关。
  • 应答的高突变结直肠癌富含细胞毒性及增殖性PD1+CD8 T细胞,这些细胞与PDL1+抗原提呈巨噬细胞相互作用。

关键数值与推荐

  • 原文未报告具体阈值或定量标准。

临床怎么用

  • 提示临床评估结直肠癌抗PD1治疗应答时,除肿瘤突变负荷外,应关注免疫原性突变克隆性及肿瘤微环境中CD8 T细胞与抗原提呈巨噬细胞的互作状态。

局限性

  • 研究样本量有限(29例患者),结论需更大规模队列验证;原文未明确报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Colorectal cancer (CRC) shows variable response to immune checkpoint blockade, which can only partially be explained by high tumor mutational burden (TMB). We conducted an integrated study of the cancer tissue and associated tumor microenvironment (TME) from patients treated with pembrolizumab (KEYNOTE 177 clinical trial) or nivolumab to dissect the cellular and molecular determinants of response to anti- programmed cell death 1 (PD1) immunotherapy. METHODS: We selected multiple regions per tumor showing variable T-cell infiltration for a total of 738 regions from 29 patients, divided into discovery and validation cohorts. We performed multiregional whole-exome and RNA sequencing of the tumor cells and integrated these with T-cell receptor sequencing, high-dimensional imaging mass cytometry, detection of programmed death-ligand 1 (PDL1) interaction in situ, multiplexed immunofluorescence, and computational spatial analysis of the TME. RESULTS: In hypermutated CRCs, response to anti-PD1 immunotherapy was not associated with TMB but with high clonality of immunogenic mutations, clonally expanded T cells, low activation of Wnt signaling, deregulation of the interferon gamma pathway, and active immune escape mechanisms. Responsive hypermutated CRCs were also rich in cytotoxic and proliferating PD1+CD8 T cells interacting with PDL1+ antigen-presenting macrophages. CONCLUSIONS: Our study clarified the limits of TMB as a predictor of response of CRC to anti-PD1 immunotherapy. It identified a population of antigen-presenting macrophages interacting with CD8 T cells that consistently segregate with response. We therefore concluded that anti-PD1 agents release the PD1-PDL1 interaction between CD8 T cells and macrophages to promote cytotoxic antitumor activity.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Bortolomeazzi M, Keddar MR, Montorsi L, et al. Immunogenomics of Colorectal Cancer Response to Checkpoint Blockade: Analysis of the KEYNOTE 177 Trial and Validation Cohorts. Gastroenterology. 2021. PMID: 34197832. doi:10.1053/j.gastro.2021.06.064

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。